Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

T. M. MacDonald, S. V. Morant, J. L. Goldstein, T. A. Burke, D. Pettitt

    Research output: Contribution to journalArticle

    81 Citations (Scopus)

    Abstract

    Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.
    Original languageEnglish
    Pages (from-to)1265-1270
    Number of pages6
    JournalGut
    Volume52
    Issue number9
    DOIs
    Publication statusPublished - 2003

    Fingerprint

    meloxicam
    Gastrointestinal Hemorrhage
    Cyclooxygenase 2 Inhibitors
    Anti-Inflammatory Agents
    Clinical Trials
    Incidence
    Pharmaceutical Preparations

    Cite this

    @article{c8351acf227d477ba2fa5d6b62cec8fe,
    title = "Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs",
    abstract = "Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.",
    author = "MacDonald, {T. M.} and Morant, {S. V.} and Goldstein, {J. L.} and Burke, {T. A.} and D. Pettitt",
    note = "dc.publisher: BMJ Publishing Group dc.description.sponsorship: Pfizer Inc., New York, USA",
    year = "2003",
    doi = "10.1136/gut.52.9.1265",
    language = "English",
    volume = "52",
    pages = "1265--1270",
    journal = "Gut",
    issn = "0017-5749",
    publisher = "BMJ Publishing Group",
    number = "9",

    }

    Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. / MacDonald, T. M.; Morant, S. V.; Goldstein, J. L.; Burke, T. A.; Pettitt, D.

    In: Gut, Vol. 52, No. 9, 2003, p. 1265-1270.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs

    AU - MacDonald, T. M.

    AU - Morant, S. V.

    AU - Goldstein, J. L.

    AU - Burke, T. A.

    AU - Pettitt, D.

    N1 - dc.publisher: BMJ Publishing Group dc.description.sponsorship: Pfizer Inc., New York, USA

    PY - 2003

    Y1 - 2003

    N2 - Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.

    AB - Although clinical trial results suggest that meloxicam has less gastrointestinal toxicity than most other non-steroidal anti-inflammatory drugs (NSAIDs), in practice it has been associated with a large number of yellow card reports of gastrointestinal complications.

    U2 - 10.1136/gut.52.9.1265

    DO - 10.1136/gut.52.9.1265

    M3 - Article

    VL - 52

    SP - 1265

    EP - 1270

    JO - Gut

    JF - Gut

    SN - 0017-5749

    IS - 9

    ER -